# Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT04054362** · PHASE2 · COMPLETED · sponsor: **Barts & The London NHS Trust** · enrollment: 27 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Paclitaxel protein bound
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT04054362
- **Lead sponsor:** Barts & The London NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-29
- **Primary completion:** 2021-02-08
- **Final completion:** 2025-02-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054362, "Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04054362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*